NCT03262103View on ClinicalTrials.gov

Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 16, 2017

Primary Completion Date

May 6, 2022

Study Completion Date

May 6, 2022

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

Intratumoral (IT) Poly ICLC 0.5 mg

0.5 mg IT once/week (week 1)

BIOLOGICAL

Intratumoral (IT) Poly ICLC 1.0 mg

1.0 mg IT once/week (week 1)

BIOLOGICAL

Intramuscular (IM) Poly ICLC

1 mg IM twice weekly (weeks 3-6)

PROCEDURE

Radical Prostatectomy

as per standard care

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

Sponsors

Collaborators (1)

Oncovir, Inc.
All Listed Sponsors
collaborator

Oncovir, Inc.

INDUSTRY

lead

Ashutosh Kumar Tewari

OTHER